Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DVS combination therapy in unfit newly diagnosed or relapsed/refractory AML and high-risk MDS
ChiCTR2300076031Phase 4Not yet recruiting
- Sponsor
- The Second Hospital of Hebei Medical University
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of decitabine, venetoclax and selinexor in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by The Second Hospital of Hebei Medical University. Primary endpoint: Complete response rate. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
decitabinevenetoclaxselinexor
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR2300076031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076031.